$1.29
+0.16 (+14.16%)
Open$1.18
Previous Close$1.13
Day High$1.33
Day Low$1.08
52W High$2.97
52W Low$0.69
Volume—
Avg Volume580.3K
Market Cap38.45M
P/E Ratio—
EPS$-1.74
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+2,849.6% upside
Current
$1.29
$1.29
Target
$38.05
$38.05
$26.78
$38.05 avg
$46.02
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.33M | 11.14M | 10.37M |
| Net Income | -3,474,981 | -2,537,744 | -2,319,778 |
| Profit Margin | -28.2% | -22.8% | -22.4% |
| EBITDA | -5,324,397 | -5,017,327 | -4,875,631 |
| Free Cash Flow | -1,460,004 | -1,340,766 | -1,751,994 |
| Rev Growth | +17.2% | +1.6% | +25.0% |
| Debt/Equity | 0.34 | 0.29 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.48 | +0.20% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $393.16 | +1.95% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.56 | +0.30% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $510.72 | +0.47% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $798.17 | +1.70% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $244.32 | +1.99% | 40.0 | 32.33B |